ABBV as reported
AbbVie reported $64.4B of revenue over the trailing twelve months, +10% on the year before. 11 reported series are charted on this page, each one as filed.
$64.4B
Revenue, trailing twelve months · to Q2 2026 · +10% against the twelve months before
- Net Income
- $6.31B
Net Income · +68% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $18.2B
Free Cash Flow · −0.16% year on year · trailing twelve months to Q2 2026
- Op Margin
- 26%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $64.4B | +10% | Q2 2026 |
| Net Income | $6.31B | +68% | Q2 2026 |
| EPS | $3.54 | +69% | Q2 2026 |
| Gross Margin | 71% | n/a | Q2 2026 |
| Op Margin | 26% | n/a | Q2 2026 |
| Net Margin | 9.5% | n/a | Q2 2026 |
| ROE | −95% | n/a | Q2 2026 |
| ROA | 3.1% | n/a | Q2 2026 |
| ROIC | 19% | n/a | Q2 2026 |
| Free Cash Flow | $18.2B | −0.16% | Q2 2026 |
| P/E | 74.3 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
AbbVie (ABBV) - Revenue & ProfitRevenue & ProfitAbbVie (ABBV)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - General
Ranks #15 of 16 by Smart Score